Of 610,000 cancers reported in 2012-19, 7.9% were childhood cases: Report

Of the 6.10 lakh cancers reported and analysed between 2012 to 2019 under the National Cancer Registry Programme (NCRP), 52.4 per cent were reported in males and 47.6 per cent in women.

Child cancer patients
Press Trust of India New Delhi
3 min read Last Updated : Sep 26 2021 | 4:03 PM IST

Of the 6.10 lakh cancers reported and analysed between 2012 to 2019 under the National Cancer Registry Programme (NCRP), 52.4 per cent were reported in males and 47.6 per cent in women.

Childhood cancers (0-14 years) comprised 7.9 per cent of all cancers, according to the report, "Clinicopathological Profile of Cancers in India: A Report of Hospital Based Cancer Registries, 2021".

Cancers in sites associated with tobacco use comprised 48.7 per cent of cancers among males and 16.5 per cent among females, it said.

A total of 13,32,207 cancer cases were registered from 96 hospitals under the NCRP during 2012-19. Of these, 6,10,084 cases were included for analysis, based on the completeness and quality of data.

The report was prepared by the Indian Council of Medical Research - National Centre for Disease Informatics and Research, Bengaluru.

According to the report, cancers of the head and neck region accounted for nearly one third (31.2 per cent) of the cancers among males. Gynaecologic cancers, including breast cancer (51 per cent), accounted for over half of all cancers in females.

The relative proportion of site-specific cancers was higher in males than females except for thyroid cancer (2.5 per cent in females versus 1 per cent in males) and gall bladder cancer (3.7 per cent in females versus 2.2 per cent in males).

The highest proportion of cancer from all sites were reported in the age group 45 to 64 years, except for prostate cancer, which was higher in those over 65. Over 90 per cent of the cancers in different organ sites got diagnosed by microscopic examination, the report said.

Among all the cancers, the highest proportion of distant metastasis at presentation was seen in patients with lung cancer (49.2 per cent males and 55.5 per cent females), followed by gall bladder cancer (40.9 per cent males and 45.7 per cent females) and prostate cancer (42.9 per cent).

Over one-third of patients with cancers of the tongue, larynx, thyroid, corpus uteri, kidney (including children), bladder and retinoblastoma had localized disease at the time of presentation.

Chemotherapy was the most typical treatment modality for many cancers regardless of the clinical extent of disease at presentation, including cancers of the liver, gall bladder, stomach, lung and childhood cancers, the report stated.

Regardless of the organ site and clinical extent, most cancer patients, were initiated on cancer-directed treatment within 8 to 30 days of diagnosis.

Over half of the patients with cancer of the brain and nervous system and about one-third of the patients of lung, prostate, bladder and thyroid cancer with localised disease, diagnosed at the reporting institution were initiated on cancer directed treatment on the same day, the report stated.

The report is based on seven-year data of cancer cases from 96 Hospital Based Cancer Registries HBCRs' under the NCRP. The data pertains to all diagnosed and treated patients of confirmed malignancies reported to these centres across the country.

Cancer surveillance is an essential part of cancer prevention and control efforts. The Indian Council of Medical Research (ICMR) started the National Cancer Registry Programme (NCRP) in 1981, through a network of Population and Hospital Based Cancer Registries (PBCRs and HBCRs).

Cancer registries systematically collect, store, analyze, interpret and generate meaningful data on cancer, which helps develop plans and implement effective evidence-based strategies.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :cancer

First Published: Sep 26 2021 | 3:50 PM IST

Next Story